Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.

Acute myeloid leukemia (AML) remains a challenging disease to treat and urgently requires new therapies to improve its treatment outcome. In this study, we investigated the molecular mechanisms underlying the cooperative antileukemic activities of panobinostat and cytarabine or daunorubicin (DNR) in...

Full description

Bibliographic Details
Main Authors: Chengzhi Xie, Christina Drenberg, Holly Edwards, J Timothy Caldwell, Wei Chen, Hiroto Inaba, Xuelian Xu, Steven A Buck, Jeffrey W Taub, Sharyn D Baker, Yubin Ge
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3823972?pdf=render

Similar Items

Similar Items